Cargando…

Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib

BACKGROUND: Patients with metastatic renal cell cancer (mRCC) are commonly treated with the tyrosine kinase inhibitor sunitinib, which blocks signalling from vascular endothelial growth factor (VEGF) - and platelet-derived growth factor-receptors, inhibiting development of new blood vessels. There a...

Descripción completa

Detalles Bibliográficos
Autores principales: Niinivirta, Marjut, Georganaki, Maria, Enblad, Gunilla, Lindskog, Cecilia, Dimberg, Anna, Ullenhag, Gustav J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179003/
https://www.ncbi.nlm.nih.gov/pubmed/32321460
http://dx.doi.org/10.1186/s12885-020-06770-z